# Silymarin's Advantage on Graft Effectiveness

Study · id `cardio:ct-nct06801886` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06801886](<https://clinicaltrials.gov/study/NCT06801886>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06801886

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 130 participants.

## Technical summary

Registry record NCT06801886. Randomized; single masking; primary purpose prevention. Start 2020-01-07 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 130 participants (planned count; ClinicalTrials.gov record NCT06801886, source copy `cardio:ctgov-nct06801886-2025-03-30`, retrieved 2026-10-26)
- Started: 2020-01-07 (actual) (ClinicalTrials.gov record NCT06801886, source copy `cardio:ctgov-nct06801886-2025-03-30`, retrieved 2026-10-26)
- Primary completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT06801886, source copy `cardio:ctgov-nct06801886-2025-03-30`, retrieved 2026-10-26)
- Completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT06801886, source copy `cardio:ctgov-nct06801886-2025-03-30`, retrieved 2026-10-26)
- Countries: Slovakia (ClinicalTrials.gov record NCT06801886, source copy `cardio:ctgov-nct06801886-2025-03-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06801886-2025-03-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Silymarin's Advantage on Graft Effectiveness
- Acronym: SAGE
- Condition: Posttransplant Diabetes Mellitus
- Condition: Acute Graft Rejection
- Condition: Biopsy Proven Acute Rejection
- Condition: Antibody Mediated Rejection of Kidney Transplant
- Condition: Arterial Hypertension, Chronic Kidney Disease
- Intervention (Drug): Silymarine supplementation
- Intervention (Other): Placebo Supplementation
- Lead sponsor: University Hospital, Martin
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: University Hospital, Martin (`cardio:org-university-hospital-martin`)

## Provenance

Content hash: 34fe96a16251a7cefd54a634ef29e49c9b856eac2fd44dd7195bfb1d1173c39f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
